Albumin-Bilirubin Score vs Model for End-Stage Liver Disease in Predicting Post-Hepatectomy Outcomes.

BACKGROUND: The Albumin-Bilirubin score (ALBI) has been established to predict outcomes after hepatectomy. However, the relative value of ALBI and Model for End-Stage Liver Disease (MELD) in predicting post-hepatectomy liver failure and mortality has not been adequately evaluated. Therefore, the aim of this study was to validate and compare ALBI and MELD with respect to post-hepatectomy liver failure and mortality. STUDY DESIGN: Patients undergoing major hepatectomy (≥3 segments) or partial hepatectomy (≤2 segments) were identified in the 2014 to 2017 American College of Surgeons NSQIP Procedure Targeted Participant Use File. Univariable and multivariable analyses were performed for 30-day post-hepatectomy liver failure (PHLF) and mortality. Predictive accuracy was assessed using a receiver operator characteristic curve and calculating the area under the curve (AUC). RESULTS: For 13,783 patients, median ALBI was -2.6, and median MELD score was 6.9. Severe PHLF (grade B to C) and mortality rates were 2.9% and 1.8%, respectively. Multivariable analyses revealed ALBI grade 2/3 to be a stronger predictor than MELD ≥10 with respect to severe PHLF (odds ratio [OR] 2.30; 95% CI, 1.95 to 2.73; p < 0.001 vs OR 1.00; 95% CI, 0.78 to 1.23; p = 0.99) and mortality (OR 3.35; 95% CI, 2.49 to 4.52; p < 0.001 vs OR 1.73; 95% CI, 1.36 to 2.20; p < 0.001). ALBI also had better discrimination compared with MELD for severe PHLF (AUC 0.67 vs AUC 0.60) and mortality (AUC 0.70 vs AUC 0.58) in patients with hepatocellular carcinoma. CONCLUSIONS: ALBI is a powerful predictor of PHLF and mortality. Compared with MELD, ALBI is more accurate, especially in patients with hepatocellular carcinoma.

What constitutes liver failure after transjugular intrahepatic portosystemic shunt creation? A proposed definition and grading system.

UNLABELLED:  Background and rationale for the study. There is currently no definition of post-transjugular intrahepatic portosystemic shunt (TIPS) liver failure (PTLF), which constitutes a barrier to standardization of TIPS results reporting and limits the ability to compare liver failure incidence across clinical studies. Thisdescriptive study proposes and preliminarily tests the performance of a PTLF definition and grading system. RESULTS: PTLF was defined by ≥ 3-fold bilirubin and/or ≥ 2-fold INR elevation associated with clinical outcomes of prolonged hospitalization/increase in care level (grade 1), TIPS reduction or liver transplantation (grade 2), or death (grade 3) within 30-days of TIPS. PTLF incidence was 20% (grades 1, 2, 3: 10%, 3%, 8%) among 270 TIPS cases, and the scheme identified patients at increased risk for morbidity and mortality with a statistically significant difference in clinical outcomes between PTLF and non-PTLF groups (P<0.0001). CONCLUSIONS: In conclusion, the PTLF definition and classification scheme put forth distributes patients into unique risk groups. PTLF grading may thus be useful for standardization of TIPS results reporting.

Pediatric liver transplantation in Latin America: Where do we stand?

LT started in LA in 1968, and pediatric LT records are available starting in the 1990s. Currently, eight countries perform pediatric LT in LA. Registries by national organizations fail to report robust data on pediatric LT. The aim of this paper was to report on the pediatric LT activity in LA. Data were gathered retrospectively through information available in the national registries websites and from local centers. Of the eight countries that report pediatric LT activity, Brazil, Argentina, Mexico, and Colombia have adequate registries of the numbers of LT performed. These countries concentrate most of the activity for pediatric LT. A total of 4593 pediatric LT were reported in LA. Websites for national organizations do not provide open data on post-transplant survival rates or waiting list mortality. The information herein is based on reports by local centers. Overall, survival from select centers is similar to that reported on North American and European registries, between 80 and 90% in the first year post-transplant. In conclusion, pediatric LT activity is growing in LA, especially in Brazil and Argentina. However, the lack of an appropriate LA registry restricts the assessment of quality and therefore restricts interventions aimed at quality improvements in different regions.

Extended preoperative chemotherapy, extent of liver resection and blood transfusion are predictive factors of liver failure following resection of colorectal liver metastasis.

AIM: The aim of this study was to determine the incidence and prognostic factors of postoperative liver failure in patients submitted to liver resection for colorectal metastases. METHOD: Patients with CLM who underwent hepatectomy from 1998 to 2009 were included in retrospective analysis. Postoperative liver failure was defined using either the 50-50 criteria or the peak of serum bilirubin level above 7 mg/dL independently. RESULTS: Two hundred and nine (209) procedures were performed in 170 patients. 120 surgeries were preceded by chemotherapy within six months. The overall morbidity rate was 53.1% and 90-day mortality was 2.3%. Postoperative liver failure occurred in 10% of all procedures, accounting for a mortality rate of 9.5% among this group of patients. In multivariate analysis, extent of liver resection, need of blood transfusion and more than eight preoperative chemotherapy cycles were independent prognostic factors of postoperative liver insufficiency. This complication was not related with the chemotherapy regimen used. CONCLUSION: We conclude that postoperative liver failure has a relatively low incidence (10%) after CLM resection, but a remarkable impact on postoperative mortality rate. The amount of liver resected, the need of blood transfusion and extended preoperative chemotherapy are independent predictors of its occurrence and this knowledge can be used to prevent postoperative liver failure in a multidisciplinary approach.

Our initial experience with ALPPS technique: encouraging results.

Surgical resection is the best option for prolonged survival in patients with primary or secondary liver tumors. A sufficient future liver remnant (FLR) volume is needed to prevent post-hepatectomy liver failure (PHLF). With the aim of increasing FLR, a new two-step technique has been recently developed. Our aim is to report our initial experience with associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique. Analysis was conducted of ten patients previously considered locally unresectable because of small FLR. During first surgical step liver parenchymal partition and portal vein ligation was performed. Seven days after the first procedure, once volumetric and functional studies have demonstrated an appropriate FLR volume, the resection of the deportalized hemiliver was achieved. This technique was successfully performed in all ten patients (feasibility 100 %). Six were male with mean age of 55.2 years (range 39-77). Mean preoperative FLR volume and FLR/total liver volume were 408.4 ml and 27.8 %. Mean postoperative FLR volume was 733 ml representing a mean volume increase of 325 ml or 82 % (range 31-140) (p < 0.0001). All resections were R0 (4 right hepatectomies, 5 right trisectionectomies and 1 left trisectionectomy). There were two grade A post-hepatectomy liver failures. Morbidity was 40 % and mortality 0 %. With a mean follow-up of 187 days, disease-free survival and overall survival were 80 and 100 %, respectively. ALPPS induces a great and fast FLR hypertrophy allowing R0 resections in patients otherwise considered unresectable because of small FLR volume, without severe PHLF and low mortality in experience centers. Further experience is needed to determine long-term outcomes.

Hepatectomy preoperative planning.

Hepatectomy can comprise excision of peripheral tumors as well as major surgeries like trisegmentectomies or central resections. Patients can be healthy, have localized liver disease or possess a cirrhotic liver with high operative risk. The preoperative evaluation of the risk of postoperative liver failure is critical in determining the appropriate surgical procedure. The nature of liver disease, its severity and the operation to be performed should be considered for correct preparation. Liver resection should be evaluated in relation to residual parenchyma, especially in cirrhotic patients, subjects with portal hypertension and when large resections are needed. The surgeon should assess the rationale for the use of hepatic volumetry. Child-Pugh, MELD and retention of indocyanine green are measures for assessing liver function that can be used prior to hepatectomy. Extreme care should be taken regarding the possibility of infectious complications with high morbidity and mortality in the postoperative period. Several centers are developing liver surgery in the world, reducing the number of complications. The development of surgical technique, anesthesia, infectious diseases, oncology, intensive care, possible resection in patients deemed inoperable in the past, will deliver improved results in the future.

Planejamento pré-operatório em hepatectomias / Hepatectomy preoperative planning

Hepatectomia pode combinar desde a captação pequeno tumor periférico para operações de grande porte como trissegmentectomia ou ressecções central. Os pacientes podem ser saudáveis, com doença hepática localizada ou cirróticos com alto risco operatório. A avaliação pré-operatória do risco de insuficiência hepática pós-operatório é fundamental para determinar o procedimento cirúrgico adequado. A natureza da doença hepática, a sua gravidade e a operação realizada devem ser considerados para correta preparação pré-operatória. A ressecção hepática deve ser avaliada em relação ao parênquima residual, especialmente em cirróticos, pacientes com hipertensão portal e grandes ressecções. O racional para a utilização de volumetria hepática é medida pelo cirurgião. Child-Pugh, MELD e retenção de verde de indocianina são medidas de avaliação da função do fígado que pode ser usado em hepatectomia pré-operatório. Extremo cuidado deve ser tomado em relação à possibilidade de complicações infecciosas com alta morbidade e mortalidade no período pós-operatório. Vários centros estão desenvolvendo a cirurgia de fígado no mundo, com diminuição do número de complicações. O desenvolvimento da técnica cirúrgica, anestesia, doenças infecciosas, oncologia, terapia intensiva, possível ressecção em pacientes considerados inoperáveis no passado, irão proporcionar melhores resultados no futuro.

Hepatectomy can comprise excision of peripheral tumors as well as major surgeries like trisegmentectomies or central resections. Patients can be healthy, have localized liver disease or possess a cirrhotic liver with high operative risk. The preoperative evaluation of the risk of postoperative liver failure is critical in determining the appropriate surgical procedure. The nature of liver disease, its severity and the operation to be performed should be considered for correct preparation. Liver resection should be evaluated in relation to residual parenchyma, especially in cirrhotic patients, subjects with portal hypertension and when large resections are needed. The surgeon should assess the rationale for the use of hepatic volumetry. Child-Pugh, MELD and retention of indocyanine green are measures for assessing liver function that can be used piror to hepatectomy. Extreme care should be taken regarding the possibility of infectious complications with high morbidity and mortality in the postoperative period. Several centers are developing liver surgery in the world, reducing the number of complications. The development of surgical technique, anesthesia, infectious diseases, oncology, intensive care, possible resection in patients deemed inoperable in the past, will deliver improved results in the future.

Trasplante hepático pediátrico estudio descriptivo de la experiencia recogida por el grupo de trasplante pediátrico de Clínica Las Condes y Hospital Luis Calvo Mackenna / Pediatric liver transplantation: descriptive study of the experience in liver transplantation at Clínica Las Condes and Luis Calvo Mackenna Hospital

El trasplante hepático pediátrico (THP) es la única alternativa de tratamiento para niños que padecen enfermedades hepáticas terminales, ya sean éstas agudas o crónicas. En Chile el THP representa aproximadamente un 20 por ciento del total de trasplantes de hígado realizados en nuestro país. Objetivo: Exponer las indicaciones, procedimientos y principales complicaciones del THP desde el punto de vista teórico y realizar un estudio descriptivo de la experiencia recogida por el grupo de trasplante pediátrico de Clínica Las Condes y Hospital Luis Calvo Mackenna desde 1994 a 2009 en esta materia. Material y Métodos: Se recolectaron los datos de 209 trasplantes hepáticos realizados a 173 pacientes menores de 18 entre 1994 y 2009 en ambos centros, realizando estadística descriptiva y curvas de sobrevida de Kaplan y Meier. Resultados: Las principales causas de trasplante fueron Atresia de Vías Biliares (48 por ciento) y Falla hepática aguda (28 por ciento). Cuarenta y un trasplantes se realizaron en niños menores de 10 kilos. Se trasplantaron con donante vivo 27 por ciento de los casos. Las complicaciones vasculares se presentaron en 13 por ciento de los casos y las biliares en 14 por ciento. Rechazos moderados o severos se diagnosticaron en 36 por ciento de los trasplantes. Enfermedad por Citomegalovirus se detectó en 30 por ciento de los pacientes dentro del primer año post trasplante y síndrome linfoproliferativo en 5 por ciento. La sobrevida actuarial de pacientes a 1 año ha sido de 76 por ciento, a 5 años de 67 por ciento y a 10 años de 65 por ciento. Conclusión: Los resultados del THP en términos de sobrevida y complicaciones es similar a la experiencia de centros extranjeros, la cual es superior a las expectativas y calidad de vida de los pacientes sin trasplante. Las áreas de mayor desarrollo de nuestro centro y que presentan los mayores desafíos son el trasplante hepático en niños menores de 10 kilos, en falla hepática aguda, y el uso de donante vivo.

Pediatric liver transplantation (PLT) is the only therapeutic option for children with acute or chronic end stage liver disease. In Chile PLT represents approximately 20 percent of all liver transplants performed. Objective: To present indications, procedures and main complications of PLT from an theoretic point of view and describe the experience achieved by the pediatric liver transplant team of Clínica Las Condes and Hospital Luis Calvo Mackenna from 1994 to 2009 in this field. Methods: Data from 209 liver transplants performed in 173 patients younger than 18 years old, between 1994 and 2009 were analyzed with descriptive statistics. Kaplan-Meier’sactuarial survival graphs were calculated. Results: The main liver diseases leading to PLT were Biliary Atresia (48 percent) and Acute Liver Failure (28 percent). Forty-one transplants were performed in children weighting b 10 kilograms. Living donor was used in 27 percent of the cases. Vascular complications occurred in 13 percent and biliary reoperations performed in 14 percent. Moderate and severe acute graft rejection was diagnosed in 36 percent of the transplants. Cytomegalovirus disease occurred in 30 percent of the cases and post transplant lymphoproliferative disease in 5 percent. Actuarial patients survival at 1 year has been 76 percent, at 5 years 67 percent and at 10 years 65 percent. Conclusion: Results of PLT in terms of survival and complications is comparable to foreign transplant centers, which is superior to life expectancy and quality of life of these patients without liver transplant. The areas that have exhibit major development in our center and represent the biggest challenge are liver transplant in small children, in patients with acute liver failure, and the use of living donors.

Chronic liver failure and concomitant distant infections are associated with high rates of neurological involvement in pyogenic spinal infections.

STUDY DESIGN: A retrospective study of a consecutive series of all patients with pyogenic spinal infections treated at a single institution over a 10-year period. OBJECTIVE: To investigate risk factors for neurologic impairment with pyogenic spinal infections. SUMMARY OF BACKGROUND DATA: Pyogenic spinal infections are frequently associated with neurologic deficit at the time of initial diagnosis. Current evidence suggests that advanced age, diabetes mellitus, rheumatoid arthritis, systemic corticosteroid therapy, impaired immune status, infection with Staphylococcus aureus, and more proximal infections are risk factors for neurologic involvement. To the authors' knowledge, however, the influence of chronic liver failure or concomitant nonspinal infection has not been previously investigated. METHODS: A review of all patients discharged with a diagnosis of pyogenic spinal infection was performed. Data were collected, including age, sex, site of infection, degree of neurologic impairment, bacterial organism isolated, and various medical comorbidities such as diabetes mellitus, rheumatoid arthritis, chronic corticosteroid therapy, chronic liver failure, chronic renal failure, smoking, human immunodeficiency virus infection, intravenous drug abuse, cancer, cardiac disease, and the presence of a distant, nonspinal site of infection. RESULTS: Fifty-five consecutive patients with pyogenic spinal infections were identified. Statistical analysis demonstrated that the presence of an epidural abscess, chronic liver failure, or a distant nonspinal infection were the only significant risk factors for neurologic involvement. CONCLUSION: The current data suggest that chronic liver failure and the presence of a distant nonspinal infection are possible risk factors for neurologic involvement in patients with pyogenic spinal infections. These risk factors have not been previously described. This knowledge warrants closer surveillance for neurologic deficit in patients with these conditions.

Prevalence of type 2 diabetes mellitus in Brazilian liver transplant candidates: negative association with HCV status.

Recently, an epidemiological association between hepatitis C virus (HCV) infection and type 2 diabetes mellitus (DM) has been reported in several studies, although many of them did not consider known risk factors in the pathogenesis of type 2 DM. The aim of this study was to assess the prevalence of type 2 DM among Brazilian HCV (+) and HCV (-) liver transplant candidates, analyzing known confounding factors for the development of type 2 DM. We conducted a cross-sectional study to evaluate the prevalence of type 2 DM among 106 liver transplant adult candidates, comparing 36 HCV (+) cirrhotic patients with 70 HCV (-) patients who developed cirrhosis from other causes. Type 2 DM was diagnosed after two consecutive fasting glucose values > or =126 mg/dL. The age, sex, and race distribution, severity of liver disease (Child-Pugh score), and family history of DM were similar in both groups, but the mean body mass index (BMI) was higher in the HCV (-) subjects (26.81 +/- 5.29 vs 24.0 +/- 4.71, P < .01) Most of the patients were Caucasians (70.75%). Type 2 DM was detected in 36.11% of HCV (+) group and in 25.71% of the HCV (-) (P = .27). A multivariate analysis revealed that family history of DM was the only significant independent predictor for DM (odds ratio = 2.55, 95% CI = 1.03 to 6.31, P = .04). In conclusion, our study did not show an association between HCV infection and Type 2 DM in Brazilian liver transplant candidates. It confirmed that the family history of DM was a determinant factor for the development of type 2 DM.

Improving access to liver transplantation: the University of Puerto Rico experience.

Liver transplantation is the only treatment for end-stage liver disease. It is costly, difficult, and not performed in Puerto Rico. For these reasons, it has been a limited option for Puerto Ricans with advanced cirrhosis, especially for those with no medical insurance to cover for the procedure. In an effort to improve access to the procedure and offer this chance of life to more Puerto Ricans facing death from complications of advanced liver disease, the Gastroenterology and Liver Diseases Division of the University of Puerto Rico, in collaboration with LifeLink Transplant Institute in Tampa, Florida and the Office of Catastrophic Funds of the Commonwealth of Puerto Rico, opened a clinic for liver transplant evaluation at the Medical Sciences Campus. The purpose of this clinic is to coordinate the pre-transplant evaluation of candidates for this therapy, provide the evaluation by the transplant surgeon in Puerto Rico, expedite the process in seriously ill patients, and offer post-transplant follow-up upon the patient's return to Puerto Rico. The purpose of this article is to describe the experience in this clinic from 1999 to 2003. One hundred ninety-three patients were seen from September 1999 to January 2003. The most common causes for liver disease were hepatitis C and alcohol, alone or in combination. One hundred thirty four were accepted as candidates for evaluation. Of these, 63 had completed the process, 33 were listed for transplantation and 21 had been transplanted by January 2003. Neither education level, marital status, health insurance nor Child score were associated with successful outcome. This clinic offers Puerto Ricans, especially those with limited resources, with a viable access to liver transplantation.

Risk factors for development of acute renal failure after liver transplantation.

BACKGROUND: Acute renal failure (ARF) is a common complication after liver transplantation (LTx). Identification of risk factors may prevent the development and attenuate the impact of ARF on patients outcome after LTX. METHODS: Retrospective analysis of variables in the pre, intra, and postoperative periods of 92 patients submitted to LTx was performed in order to identify risk factors for development of ARF after LTx. ARF was defined as serum creatinine > or = 2.0 mg/dL in the first 30 days after LTx. Univariate and multivariate analysis by logistic regression were performed. RESULTS: ARF group comprised 56 patients (61%). Preoperative serum creatinine was higher in ARF group. During the intraoperative period, ARF group required more blood transfusions, developed more episodes of hypotension and presented longer anesthesia time. In the postoperative period, ARF group presented higher serum bilirubin and more episodes of hypotension. Dialysis was required in 10 patients (11%). The identifled risk factors for development of ARF were: preoperative serum creatinine > 1.0 mg/dL. more than five blood transfusions in the intraoperative period, hypotension during intra and postoperative periods. The identified mortality risk factors were hypotension in the postoperative period and no recovery of renal function after 30 days. CONCLUSIONS: Several factors are involved in the pathogenesis of ARF after LTx and may influence patients outcome and mortality. Pretransplant renal function and hemodynamic conditions in the operative and postoperative periods were identified as risk factors for development of ARF after LTx. Nonrenal function recovery and postoperative hypotension were identified as mortality risk factors after LTx.

Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell Histiocytosis.

OBJECTIVE: To analyze features and outcomes of cholestasis, sclerosing cholangitis (SC), and liver transplantation (LTx) in patients with Langerhans cell Histiocytosis (LCH) between October 1987 and June 1999. STUDY DESIGN: Of 182 cases with LCH, 36 had hepatic involvement and 12 of those presented with cholestasis. These 12 were the focus of our study. Their median age was 23 months (range: 3-36). Hepatomegaly or hepatosplenomegaly was found in 11 of the 12; elevations of alkaline phosphatase, transaminases, gamma glutamyl transpeptidase (GGT), and less frequently direct bilirubin were detected. Sonography, liver biopsy, and cholangiography were consistent with the diagnosis of SC in 11 patients. None of the biopsies revealed Langerhans cells (LC). Frequently associated lesions of skin, bone, and ear were noted. Early patients were treated with Vinblastine/prednisone for 8 weeks, later patients with the LCH I and LCH II protocols of the Histiocyte Society (HS). RESULTS: Median follow-up was 28 months (range: 10-86). Three patients improved and remained without signs of progressive SC at 27, 32, and 86 months. Nine had progressive liver sequelae resistant to chemotherapy. Of these nine, five received LTx, three died before LTx with progressive SC, and one awaits LTx. Three LTx patients survive without disease reactivation 14, 25, and 37 months post-transplant. Two patients died less than one month after LTx, due to renal failure and sepsis in the first patient and bowel volvulus with perforation followed by sepsis in the second one. CONCLUSIONS: SC is a frequent and usually progressive sequela of multisystem LCH in our institution. LTx has become the treatment of choice for the majority of patients and should be considered early in cases with severe hepatic involvement.

An outbreak of fulminant hepatitis delta in the Waorani, an indigenous people of the Amazon basin of Ecuador.

An outbreak of delta hepatitis occurred during 1998 among the Waorani of the Amazon basin of Ecuador. Among 58 people identified with jaundice, 79% lived in four of 22 Waorani communities. Serum hepatitis B surface antigen (HBsAg) was found in the sera of 54% of the jaundiced persons, and 14% of asymptomatic persons. Ninety-five percent of 105 asymptomatic Waorani had hepatitis B core (HBc) IgG antibody, versus 98% of 51 with jaundice. These data confirm that hepatitis B virus (HBV) infection is highly endemic among the Waorani. Sixteen of 23 (70%) HBsAg carriers identified at the onset of the epidemic had serologic markers for hepatitis D virus (HDV) infection. All 16 were jaundiced, where as only two of seven (29%) with negative HDV serology were jaundiced (P = .0006). The delta cases clustered in families, 69% were children and most involved superinfection of people chronically infected with HBV. The data suggest that HDV spread rapidly by a horizontal mode of transmission other than by the sexual route.